1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cardax, Inc.

Cardax, Inc.

CDXI
Cardax, Inc.US flagOther OTC
0.00
USD
- -
- -
80.00Market Cap
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
TTM
Revenue per Share
0.33
0.33
- -
- -
0.09
1.22
2.37
1.05
0.72
0.65
Basic EPS, GAAP
-0.04
-0.28
-56.44
-12.73
-4.68
-3.97
-6.32
-7.49
-6.79
-7.08
Free Cash Flow per Basic Share
-0.07
-0.13
-19.01
-4.57
-3.37
-4.2
-5.08
-5.27
-2.43
-2.04
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
-165.47
-161.74
-146.53
-115.65
-97.24
-98.56
-96.82
-95.7
Tangible Book Value per Share
0.12
-0.04
-12.07
-12.48
-11.32
-3.67
-6.23
-11.2
-14.1
-15.16
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
1
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
1
2
1
1
1
Operating Margin (%)
-13.39
-46.65
- -
- -
-5,190.95
-328.07
-266.24
-573.47
-568.26
-584.76
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-17
-4
-2
-2
-4
-5
-5
-5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-13.39
-86.47
- -
- -
-5,059.01
-325.28
-266.35
-716.37
-938.04
-1,085.42
Working Capital
- -
- -
-4
-4
-4
-2
-4
-7
-9
-11
LT Debt
- -
- -
- -
- -
- -
- -
- -
1
1
- -
Total Equity
- -
- -
-3
-4
-4
-1
-4
-7
-10
-11
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-6,187.65
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'20
Dec'20
Mar'21
ST Debt
3
4
5
LT Borrowings
1
1
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
2
1
2

Working Capital

FRC

•

in mil. unless spec.
Sep'20
Dec'20
Mar'21
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
1
1
1
Total Current Liabilities
10
11
12
Payables & Accruals
6
6
7
ST Debt
3
4
5
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
47.33%
41.66%
Free Cash Flow
- -
12.54%
-49.61%
Net Income, GAAP
- -
16.34%
-0.74%
Sales/Revenue/Turnover
- -
329.65%
-24.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
1
2020
- -
- -
- -
- -
1
2021
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
-1.69
-1.59
-2.1
- -
-7.49
2020
-1.43
-2.26
-1.79
- -
-6.79
2021
-1.74
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David G. Watumull
Full Time Employees
10
Sector
Healthcare
Industry
Biotechnology
Address
2800 Woodlawn Drive Honolulu HI United States of America 96822
IPO Date
Mar 6, 2013
CIK
0001544238
Website
cardaxpharma.com
Similar Companies
Bio-Path Holdings, Inc. (BPTH)
Formycon AG (FYB.DE)
Circio Holding ASA (CRNA.OL)
Shattuck Labs, Inc. (STTK)
Polaryx Therapeutics, Inc. Common Stock (PLYX)
Race Oncology Limited (RAC.AX)
Business
Cardax, Inc. (CDXI) operates as a consumer health company that develops, markets and sells dietary supplements focused on inflammatory health; it also pursues pharmaceutical candidates targeting inflammation-driven chronic diseases. The company offers ZanthoSyn, a physician-recommended astaxanthin dietary supplement with enhanced absorption and purity for health, longevity and inflammatory conditions including cardiovascular inflammation, available via e-commerce and wholesale channels through www.zanthosyn.com; it develops pre-clinical pharmaceutical CDX-101, an astaxanthin prodrug candidate for cardiovascular inflammation, dyslipidemia and severe hypertriglyceridemia, and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax serves the biotechnology and healthcare sectors, targeting consumers, physicians and patients with inflammatory and age-related conditions in the United States. Founded through a 2006 asset acquisition from Hawaii Biotech, Inc. and publicly listed since 2014, the company maintains headquarters at 2800 Woodlawn Drive, Suite 129, Honolulu, Hawaii. In recent developments, Cardax refocuses operations on its ZanthoSyn consumer health business while exploring monetization of pharmaceutical assets; it secured $0.75 million via a senior convertible promissory note and raised $0.45 million through a private placement of 5.66 million units at $0.08 per unit, reflecting ongoing funding efforts amid limited strategic alliances or acquisitions within the last two years.